The strategic challenge is converting this health and sustainability credibility into consistent revenue growth above the 3-5% target range, particularly in European dairy where private-label competition and mature demand constrain pricing power, and in China where birth-rate declines threaten the infant formula cash cow. Danone's high-protein yogurt platforms, which grew double-digit in FY2024, position the company to capture consumers seeking protein-rich foods to counter muscle loss from semaglutide medications — a trend CEO Antoine de Saint-Affrique explicitly referenced in the February 2025 earnings call, noting 'we see, by the way, no slowing down of the GLP-1 trend in the US.' This trend benefits Danone's high-protein and medical nutrition segments while potentially threatening traditional snack and dessert categories. Second, China's birth-rate decline poses a direct and structural threat to Danone's most profitable segment. The company faces acute challenges from private-label competition in European dairy, where price elasticity remains high and retailers like Lidl, Aldi, and Carrefour capture 30-40% of yogurt volume in Germany and the UK.
In 2024, Danone's top ten customers worldwide accounted for approximately 20% of consolidated sales, with the top five representing approximately 14%, indicating moderate customer concentration risk. Danone faces five interconnected challenges that threaten margin stability and market share in the near term, each with distinct financial implications and strategic responses. Fifth, the competitive landscape intensifies across all segments, with each arena presenting distinct threats. Yet Medical nutrition operates under even stricter regulations: Danone's Fortimel and Nutrison products are classified as Foods for Special Medical Purposes (FSMP) in the EU, requiring pre-market authorization, clinical evidence, and healthcare professional recommendation.